Novartis and Bristol Myers Squibb Pause Cell Therapy Trials Amid $480K Cancer Drug Pricing
Source Summary
Novartis and Bristol Myers Squibb have paused multiple cell therapy trials. A cancer drug price of $480,000 has become routine in the pharmaceutical market.
Why it matters
Cell therapy trial pauses and escalating cancer drug costs reflect significant developments in pharmaceutical development and healthcare affordability.
